Cutaneous T-cell lymphoma
Conditions
Interventions
Subjects will be randomized 1:1 to receive either KW-0761 or vorinostat.
Treatment will be administered on an
outpatient basis. The dose of KW-0761 will be 1.0 mg/kg. The dose of vorinostat
will be
Sponsors
Kyowa Kirin Pharmaceutical Development Inc.
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1) Voluntarily signed and dated Institutional Review Board / Ethics Committee approved informed consent form in accordance with regulatory and institutional guidelines. Written informed consent must be obtained prior to performing any study-related procedure; 2) Males and female subjects >= 18 years of age at the Pre-treatment Visit, i.e., at the time that written informed consent is obtained, except in Japan where subjects must be >= 20 years of age; 3) Histologically confirmed diagnosis of MF or SS; For SS (defined as meeting T4 plus B2 criteria), where the biopsy of erythrodermic skin may only reveal suggestive but not diagnostic histopathologic features, the diagnosis may be based on either a node biopsy or fulfillment of B2 criteria including a clone in the blood that matches that of the skin. 4) Stage IB, II-A, II-B, III and IV; 5) Subjects who have failed at least one prior course of systemic therapy (e.g., interferon, denileukin diftitox, bexarotene, photopheresis, anti-neoplastic chemotherapy, etc.); Psoralen plus ultraviolet light therapy (PUVA) is not considered to be a systemic therapy; 6) Eastern Cooperative Oncology Group (ECOG) performance status score of = 1,500 cells/µL (>= 1,500/mm3) b. platelets >= 100,000 cells/µL; (>= 100,000/mm3) c. in subjects with known bone marrow involvement, ANC must be >= 1,000 cells/µL (>= 1,000/mm3) and platelets >= 75,000 cells/µL. (>= 75,000/mm3) 9) Adequate hepatic function: a. bilirubin = 200/mm3. 12) Subjects with MF and a known history of non-complicated staphylococcus infection/colonization are eligible provided they continue to receive stable doses of prophylactic antibiotics. 13) Women of childbearing potential (WOCBP) must have a negative pregnancy test within 7 days of receiving study medication. 14) WOCBP must agree to use effective contraception, defined as oral contraceptives, double barrier method (condom plus spermicide or diaphragm plus spermicide) or practice true abstinence from sexual intercourse (periodic abstinence, e.g., calendar, ovulation, symptothermal, post-ovulation methods and withdrawal are not acceptable methods of contraception) during the study and for 3 months after the last dose. WOCBP includes any female who has experienced menarche and who has not undergone successful surgical sterilization or is not postmenopausal (defined as amenorrhea >= 12 consecutive months without an alternative medical cause); 15) Male subjects and their female partners of child bearing potential must be willin
Exclusion criteria
Exclusion criteria: 1) Current evidence of large cell transformation (LCT). Subjects with clinical features suggestive of LCT must have a biopsy performed within 4 months prior to Cycle 1 Day 1 to rule out transformed disease. Subjects with a history of LCT but without current aggressive disease and no current evidence of LCT on pathology in skin or lymph nodes would be eligible;;2) Diagnosed with a malignancy in the past two years. However, subjects with non-melanoma skin cancers, melanoma in situ, localized cancer of the prostate with current prostate-specific antigen of 160 mm Hg or diastolic BP > 100 mm Hg, found on two consecutive measurements separated by a 1-week period) despite two anti-hypertensive medications;;f. clinically significant cardiac arrhythmia; or;g. uncontrolled diabetes.;6) Known or tests positive for human immunodeficiency virus, human T-cell leukemia virus, hepatitis B or hepatitis C.;7) Active herpes simplex or herpes zoster. Subjects on prophylaxis for herpes who started taking medication at least 30 days prior Pre-treatment visit, and have no active signs of active infection, and whose last active infection was more than 6 months ago, may enter the study, and should continue to take the prescribed medication for the duration of the study.;8) Experienced allergic reactions to monoclonal antibodies or other therapeutic proteins.;9) Known active autoimmune disease will be excluded. (For example; Graves* disease; systemic lupus erythematosus; rheumatoid arthritis; Crohn*s disease; psoriasis).;10) Is pregnant (confirmed by beta human chorionic gonadotrophin [β-HCG]) or lactating.;11) Prior treatment with KW-0761.;12) Prior treatment with vorinostat. Patients who were exposed to vorinostat for a short time, did not progress while on treatment, and did not have intolerable toxicity but were discontinued for another reason (e.g. comorbidity) may be permitted to enter the study after discussion with the Medical Monitor.;13) Have had any therapy directed against the subject*s underlying cancer or any investigational medications within four weeks of randomization (skin directed treatments, including topicals and radiation within two weeks of randomization). However, subjects with rapidly progressive malignant disease may be enrolled prior to this period after discussion with the Medical Monitor.;14) Subjects on a stable dose of a low dose systemic corticosteroid (<= 20 mg prednisone equivalent) for at least 4 weeks prior to Pre-treatment Visit may continue use although the investigator should attempt to taper the use to the lowest dosage tolerable while on study. Initiation of treatment with systemic c
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • To compare the progression free survival of KW-0761 versus vorinostat for subjects with relapsed or refractory Cutaneous T-Cell Lymphoma (CTCL). | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the overall response rate of KW-0761 versus vorinostat in subjects with relapsed or refractory CTCL; • To evaluate and compare improvements in Quality of Life (QoL) measurements, Skindex-29, FACT-G, and EQ-5D-3L for subjects receiving KW-0761 versus vorinostat; • To evaluate and compare improvements in the Pruritus Evaluation (Likert scale & Itchy QoL) for subjects receiving KW-0761 versus vorinostat; • To estimate the duration of response for both the KW-0761 and vorinostat arms for those subjects with relapsed or refractory CTCL responding to treatment; • To determine if subjects who relapse on vorinostat can achieve response upon cross over to treatment with KW-0761; • To further assess the safety of KW-0761; • To describe the immunogenicity of KW-0761; To compare the overall survival of KW-0761 versus vorinostat for subjects with relapsed or refractory CTCL. • To conduct exploratory evaluation of KW-0761exposure-response relationships | — |
Countries
Netherlands
Outcome results
None listed